Clinicopathological characteristics and prognostic analysis of PIK3CA mutation in breast cancer patients in Northwest China

被引:0
作者
Lv, Wei [1 ]
Du, Chong [1 ]
Zhang, Yinbing [1 ]
Wu, Fei [1 ]
Jin, Yaofeng [2 ]
Chen, Xi [1 ]
Liu, Xuan [1 ]
Feng, Cong [1 ]
Ma, Xingcong [1 ]
Zhang, Shuqun [1 ]
机构
[1] Xi An Jiao Tong Univ, Dept Oncol, Affiliated Hosp 2, Xian 710004, Shaanxi, Peoples R China
[2] Xi An Jiao Tong Univ, Dept Pathol, Affiliated Hosp 2, Xian 710004, Shaanxi, Peoples R China
基金
中国国家自然科学基金;
关键词
Breast cancer; PIK3CA mutation; Northwest China; Prognosis; Targeted therapy; PI3K-AKT-MTOR PATHWAY; INSULIN-SECRETION; HIGH-FREQUENCY; PI3K PATHWAY; GENE; METABOLISM; RESISTANCE; 3-KINASES; SURVIVAL;
D O I
10.1016/j.prp.2022.154063
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Purpose: Multiple studies on PIK3CA mutations in breast cancer (BC) had been performed, which showed the controversial results among different countries and races even those from the same country. The present study aimed to explore the PIK3CA gene mutation status in BC patients in Northwest China and reveal the relationship between PIK3CA mutations and clinicopathological features along with prognosis.Materials and methods: 1002 BC patients from Northwest China were recruited in this study, genomic DNA was extracted from formalin-fixed paraffin-embedded (FFPE) tumor tissues, and hotspot mutations in the exon 9 and 20 of PIK3CA gene were detected by ARMS-PCR.Results: PIK3CA mutations were found in 31.2% (313/1002) of BC patients, among them 66.1% were mutations in exon 20% and 32.6% were mutations in exon 9. H1047R was the most common mutation type, accounting for 56.5% of the total mutated samples. Significant correlations were observed between PIK3CA mutation status and age (P = 0.035), histopathologic types (P = 0.004), pathological grade (P = 0.013), ER positivity (P < 0.001), PR positivity (P < 0.001), molecular subtypes (P = 0.004) and family history (P = 0.007). Cox multivariate analysis showed that patients with mutations in exon 9 or 20 had shorter DFS and OS than wild-type patients. Those with exon 9 mutations subgroup had the worst prognosis. Interestingly, patients with H1047L mutation had the best prognosis than others. Conclusion: PIK3CA mutations could be used as an indicator of clinical outcome or targeted therapy for multiple breast cancer subgroups in Northwest China.
引用
收藏
页数:12
相关论文
共 45 条
  • [1] Molecular evaluation of PIK3CA gene mutation in breast cancer: determination of frequency, distribution pattern and its association with clinicopathological findings in Indian patients
    Ahmad, Firoz
    Badwe, Anuya
    Verma, Geeta
    Bhatia, Simi
    Das, Bibhu Ranjan
    [J]. MEDICAL ONCOLOGY, 2016, 33 (07)
  • [2] Overcoming endocrine resistance in hormone receptor-positive breast cancer
    AlFakeeh, A.
    Brezden-Masley, C.
    [J]. CURRENT ONCOLOGY, 2018, 25 : S18 - S27
  • [3] Analysis of PIK3CA Mutations in Breast Cancer Subtypes
    Arsenic, Ruza
    Lehmann, Annika
    Budczies, Jan
    Koch, Ines
    Prinzler, Judith
    Kleine-Tebbe, Anke
    Schewe, Christiane
    Loibl, Sibylle
    Dietel, Manfred
    Denkert, Carsten
    [J]. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2014, 22 (01) : 50 - 56
  • [4] Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas
    Barbareschi, Mattia
    Buttitta, Fiamma
    Felicioni, Lara
    Cotrupi, Sabrina
    Barassi, Fabio
    Del Grammastro, Maela
    Ferro, Antonella
    Palma, Paolo Dalla
    Galligioni, Enzo
    Marchetti, Antonio
    [J]. CLINICAL CANCER RESEARCH, 2007, 13 (20) : 6064 - 6069
  • [5] ASCO 2020: highlights in breast cancer
    Bartsch, Rupert
    [J]. MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2021, 14 (01) : 58 - 61
  • [6] Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019
    Burstein, H. J.
    Curigliano, G.
    Loibl, S.
    Dubsky, P.
    Gnant, M.
    Poortmans, P.
    Colleoni, M.
    Denkert, C.
    Piccart-Gebhart, M.
    Regan, M.
    Senn, H. -J.
    Winer, E. P.
    Thurlimann, B.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 (10) : 1541 - 1557
  • [7] PIK3CA mutation and histological type in breast carcinoma:: high frequency of mutations in lobular carcinoma
    Buttitta, F
    Felicioni, L
    Barassi, F
    Martella, C
    Paolizzi, D
    Fresu, G
    Salvatore, S
    Cuccurullo, F
    Mezzetti, A
    Campani, D
    Marchetti, A
    [J]. JOURNAL OF PATHOLOGY, 2006, 208 (03) : 350 - 355
  • [8] Mutation of the PIK3CA gene in ovarian and breast cancer
    Campbell, IG
    Russell, SE
    Choong, DYH
    Montgomery, KG
    Ciavarella, ML
    Hooi, CSF
    Cristiano, BE
    Pearson, RB
    Phillips, WA
    [J]. CANCER RESEARCH, 2004, 64 (21) : 7678 - 7681
  • [9] The phosphoinositide 3-kinase pathway
    Cantley, LC
    [J]. SCIENCE, 2002, 296 (5573) : 1655 - 1657
  • [10] The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
    Cerami, Ethan
    Gao, Jianjiong
    Dogrusoz, Ugur
    Gross, Benjamin E.
    Sumer, Selcuk Onur
    Aksoy, Buelent Arman
    Jacobsen, Anders
    Byrne, Caitlin J.
    Heuer, Michael L.
    Larsson, Erik
    Antipin, Yevgeniy
    Reva, Boris
    Goldberg, Arthur P.
    Sander, Chris
    Schultz, Nikolaus
    [J]. CANCER DISCOVERY, 2012, 2 (05) : 401 - 404